Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2379 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
DSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Couleur et forme :Odour SolidAST5902
CAS :AST5902 is the active metabolite of Alflutinib.Formule :C27H29F3N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :554.57TL13-110
CAS :Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Formule :C49H62ClN9O9SCouleur et forme :SolidMasse moléculaire :988.59FGFR1 inhibitor-2
CAS :FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.Formule :C25H22F5N3O3Couleur et forme :SolidMasse moléculaire :507.461EGFR-IN-83
EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50Formule :C22H17F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.39IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Couleur et forme :Odour LiquidAnticancer agent 271
Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.Couleur et forme :Odour SolidRR-src
CAS :Tyrosine kinase substrate peptideFormule :C64H106N22O21Degré de pureté :98%Couleur et forme :Lyophilized PowderMasse moléculaire :1519.66EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Formule :C46H54N8O8Couleur et forme :SolidMasse moléculaire :846.97EGFR-IN-78
EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.Formule :C23H32BrN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.51Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formule :C36H35FN6O10Couleur et forme :SolidMasse moléculaire :730.696MLK3-IN-1
MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.Formule :C20H16F6N4O2SCouleur et forme :SolidMasse moléculaire :490.422SNIPER(ABL)-058
CAS :SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL proteinFormule :C62H75N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1150.39FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formule :C20H22FN5O2Couleur et forme :SolidMasse moléculaire :383.42AMX-818
AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.Couleur et forme :Odour LiquidBCPyr
CAS :BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formule :C58H65F2N11O8Couleur et forme :SolidMasse moléculaire :1082.224Varlitinib Tosylate
CAS :Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formule :C36H35ClN6O8S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :811.34Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS :Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formule :C51H65N17O19P2S2·xC6H15NCouleur et forme :SolidMasse moléculaire :1447.44HG-7-85-01
CAS :HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.Formule :C31H31F3N6O2SDegré de pureté :98.08%Couleur et forme :SolidMasse moléculaire :608.68hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFormule :C23H26N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :498.55MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFormule :C29H29N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.59PROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.Formule :C40H42N12O5Masse moléculaire :770.34011hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Formule :C22H23FN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.52E7090
CAS :E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.Formule :C32H37N5O6Couleur et forme :SolidMasse moléculaire :587.67VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Couleur et forme :Odour SolidDBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formule :C68H86ClFN16O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1277.96PROTAC FLT-3 degrader 1
CAS :PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.Formule :C52H61N9O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.23JAK1/TYK2-IN-1
CAS :JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Couleur et forme :Odour SolidAKN-028
CAS :AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Formule :C17H14N6Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :302.33SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36Lyso-Monosialoganglioside GM3
CAS :Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.Formule :C41H74N2O20Couleur et forme :SolidMasse moléculaire :915.028PROTAC FLT3/CDK9 degrader-1
Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.Formule :C48H62N12O7Couleur et forme :SolidMasse moléculaire :919.08Multi-kinase-IN-5
Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,Formule :C19H15N5O2SCouleur et forme :SolidMasse moléculaire :377.42Ibrutinib-biotin
CAS :Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formule :C56H80N12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1097.39PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormule :C43H40N10O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :792.84JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161Abl Cytosolic Substrate
CAS :Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formule :C64H101N15O16Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1336.58Syk-IN-4
Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.Couleur et forme :SolidEGFR-IN-22
CAS :EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).Formule :C38H47BrFN10O2PCouleur et forme :SolidMasse moléculaire :805.72PROTAC EGFR degrader 5
CAS :PROTAC EGFR degrader 5 effectively breaks down EGFR Del19 in HCC827 cells at 34.8 nM, inducing apoptosis and G1 arrest.Formule :C57H72FN13O5SCouleur et forme :SolidMasse moléculaire :1070.33dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Formule :C39H45ClN7O5PCouleur et forme :SolidMasse moléculaire :758.245SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Formule :C68H84N12O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1213.47BV02
CAS :BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.Formule :C20H15N3O5Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :377.35Ref: TM-T60081
2mg34,00€5mg52,00€10mg80,00€25mg161,00€50mg245,00€100mg363,00€200mg515,00€1mL*10mM (DMSO)58,00€BMS-599626 2HCL(714971-09-2 Free base)
CAS :BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.Formule :C27H29Cl2FN8O3Degré de pureté :99.11%Couleur et forme :Odour SolidMasse moléculaire :603.47FGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Formule :C26H27N4O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :522.49GBD-9
CAS :GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formule :C44H47N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.9hCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formule :C21H17FN6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.46
